Stock Track | MEDBOT-B Soars 6.53% Intraday on UBS Upgrade, European Certification and Surging Revenue Targets

Stock Track04-15

MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.

The rally was primarily fueled by UBS upgrading the surgical robotics company from "Neutral" to "Buy" and significantly raising its target price. The investment bank highlighted the firm's explosive overseas growth, with revenue surging 287% year-over-year and sales of its Toumai surgical robot increasing more than fivefold.

Concurrently, the company achieved a significant milestone as its self-developed Honghu orthopedic surgical robot obtained European CE certification, marking it as the first domestically developed joint replacement surgical robot to reach this standard. The sector also continues to benefit from supportive policies in China promoting the adoption of surgical robots in hospitals. Management aims to double total revenue in 2026 and expects overseas revenue to exceed 80% of the total, potentially leading to breakeven in the first half of the year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1147912088?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-15 14:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147912088","market":"hk","top_or_hot":-1,"title":"Stock Track | MEDBOT-B Soars 6.53% Intraday on UBS Upgrade, European Certification and Surging Revenue Targets","media":"Stock Track","content":"<p>MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.</p><p>The rally was primarily fueled by UBS upgrading the surgical robotics company from \"Neutral\" to \"Buy\" and significantly raising its target price. The investment bank highlighted the firm's explosive overseas growth, with revenue surging 287% year-over-year and sales of its Toumai surgical robot increasing more than fivefold.</p><p>Concurrently, the company achieved a significant milestone as its self-developed Honghu orthopedic surgical robot obtained European CE certification, marking it as the first domestically developed joint replacement surgical robot to reach this standard. The sector also continues to benefit from supportive policies in China promoting the adoption of surgical robots in hospitals. Management aims to double total revenue in 2026 and expects overseas revenue to exceed 80% of the total, potentially leading to breakeven in the first half of the year.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | MEDBOT-B Soars 6.53% Intraday on UBS Upgrade, European Certification and Surging Revenue Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | MEDBOT-B Soars 6.53% Intraday on UBS Upgrade, European Certification and Surging Revenue Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-15 14:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.</p><p>The rally was primarily fueled by UBS upgrading the surgical robotics company from \"Neutral\" to \"Buy\" and significantly raising its target price. The investment bank highlighted the firm's explosive overseas growth, with revenue surging 287% year-over-year and sales of its Toumai surgical robot increasing more than fivefold.</p><p>Concurrently, the company achieved a significant milestone as its self-developed Honghu orthopedic surgical robot obtained European CE certification, marking it as the first domestically developed joint replacement surgical robot to reach this standard. The sector also continues to benefit from supportive policies in China promoting the adoption of surgical robots in hospitals. Management aims to double total revenue in 2026 and expects overseas revenue to exceed 80% of the total, potentially leading to breakeven in the first half of the year.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02252","symbol_name":"微创机器人-B","start_time":0,"source_url":"","article_id":"1147912088","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147912088","pubTimestamp":1776233600,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.The rally was...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02252":"微创机器人-B"},"translate_title":"个股追踪|MEDBOT-B盘中大涨6.53%瑞银升级、欧洲认证和收入目标飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02252":1},"content_text":"MEDBOT-B's stock surged 6.53% during intraday trading on Wednesday, driven by a combination of a major analyst upgrade, a key regulatory milestone, and robust financial targets.The rally was primarily fueled by UBS upgrading the surgical robotics company from \"Neutral\" to \"Buy\" and significantly raising its target price. The investment bank highlighted the firm's explosive overseas growth, with revenue surging 287% year-over-year and sales of its Toumai surgical robot increasing more than fivefold.Concurrently, the company achieved a significant milestone as its self-developed Honghu orthopedic surgical robot obtained European CE certification, marking it as the first domestically developed joint replacement surgical robot to reach this standard. The sector also continues to benefit from supportive policies in China promoting the adoption of surgical robots in hospitals. Management aims to double total revenue in 2026 and expects overseas revenue to exceed 80% of the total, potentially leading to breakeven in the first half of the year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1147912088","isCrawlerRequest":true}